New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 10, 2011
17:17 EDTMAXYMaxygen announces final rejection of '804 patent in inter partes reexamination
Maxygen announced that the United States Patent and Trademark Office has issued a Right of Appeal Notice in the inter partes reexamination proceeding for Amgen's U.S. Pat. No. 7,381,804, or the '804 patent, that includes a final rejection of all claims in the '804 patent. Amgen's '804 patent includes certain claims to mutated granulocyte colony stimulating factor molecules that potentially cover Maxygen's MAXY-G34 product candidate, a next-generation, pegylated G-CSF. Maxygen submitted the request to the PTO for an inter partes reexamination of the Amgen patent in 2009. Amgen has the right to appeal the decision to the PTO's Board of Patent Appeals and Interferences.
News For MAXY From The Last 14 Days
Check below for free stories on MAXY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for MAXY

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use